On August 11, Bicara Therapeutics (NASDAQ:BCAX) used its second-quarter earnings call to deliver two headlines at once. CEO Claire Mazumdar announced she will step into a Vice Chair and Strategic Adviser role at the start of next year, handing the top job to President and Chief Operating Officer Ryan Cohlhepp. That handoff arrives just as the company points to fresh survival data for ficerafusp alfa, its lead drug candidate for frontline recurrent or metastatic HPV-negative head and neck cancer, and pushes its pivotal trial toward a critical readout.
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective **** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and **** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#bicara #three #survival #cancer
At May's ASCO meeting, Bicara presented three-year follow-up data spanning roughly 90 patients across three dose cohorts, the longest follow-up reported for any investigational agent in HPV-negative head and neck cancer. At the 1,500 milligram weekly pivotal dose, about one in three patients was still alive at three years, roughly double the survival rate seen in retrospective **** yses of standard-of-care pembrolizumab in this population. Management ties that benefit to the drug's TGF-beta inhibition, which it says drives tumor penetration and immune cell infiltration rather than blocking a single pathway. Overall survival nearly doubled against the standard of care while the safety profile stayed consistent, the company said.
Execution on the pivotal Phase III FORTIFI-HN01 study has kept pace. Bicara says it is on track for substantial enrollment by the end of 2026, with more than 200 sites now active, positioning the trial for a mid-2027 interim readout that could open the door to accelerated approval. The company also launched FORTIFI-FLEX, a study of an every-three-week maintenance dose built on encouraging results from an exploratory every-two-week cohort shown earlier this year, with data targeted for the time of any U.S. approval decision. Beyond the core indication, Bicara points to early proof of concept in cutaneous squamous cell carcinoma and **** canal cancer, backed by roughly $497 million in cash that management says funds operations through the first half of 2029.
The leadership overhaul goes well beyond the CEO chair. Jenn Larson took over as Chief Financial Officer the day after the call, succeeding Ivan Hyep, who had a hand in raising over $800 million for the company since its early days. Two more transitions take effect in January: Chief Development Officer Tanya Green moves into the Chief Operating Officer seat, and Chief Corporate Affairs Officer Jenna Cohen becomes Chief Business Officer. A new Chief Legal Officer and two new board members are joining as well, a lot of change concentrated in a single quarter right as the company approaches its most consequential trial milestone.
#bicara #three #survival #cancer
2 hours ago
